| Active, not recruiting | 2 | 60 | US | Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo | Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc. | Primary Biliary Cholangitis | 11/24 | 02/25 | | |
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) |
|
|
| Active, not recruiting | 2 | 24 | US | zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension | Kezar Life Sciences, Inc. | Autoimmune Hepatitis | 02/25 | 08/25 | | |